The New England journal of medicine, 2019-11, Vol.381 (21), p.2020-2031
- Hellmann, Matthew D
- Paz-Ares, Luis
- Bernabe Caro, Reyes
- Zurawski, Bogdan
- Kim, Sang-We
- Carcereny Costa, Enric
- Park, Keunchil
- Alexandru, Aurelia
- Lupinacci, Lorena
- de la Mora Jimenez, Emmanuel
- Sakai, Hiroshi
- Albert, Istvan
- Vergnenegre, Alain
- Peters, Solange
- Syrigos, Konstantinos
- Barlesi, Fabrice
- Reck, Martin
- Borghaei, Hossein
- Brahmer, Julie R
- O’Byrne, Kenneth J
- Geese, William J
- Bhagavatheeswaran, Prabhu
- Rabindran, Sridhar K
- Kasinathan, Ravi S
- Nathan, Faith E
- Ramalingam, Suresh S
2019
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Hellmann, Matthew D
- Paz-Ares, Luis
- Bernabe Caro, Reyes
- Zurawski, Bogdan
- Kim, Sang-We
- Carcereny Costa, Enric
- Park, Keunchil
- Alexandru, Aurelia
- Lupinacci, Lorena
- de la Mora Jimenez, Emmanuel
- Sakai, Hiroshi
- Albert, Istvan
- Vergnenegre, Alain
- Peters, Solange
- Syrigos, Konstantinos
- Barlesi, Fabrice
- Reck, Martin
- Borghaei, Hossein
- Brahmer, Julie R
- O’Byrne, Kenneth J
- Geese, William J
- Bhagavatheeswaran, Prabhu
- Rabindran, Sridhar K
- Kasinathan, Ravi S
- Nathan, Faith E
- Ramalingam, Suresh S
- Titel
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- Ist Teil von
- The New England journal of medicine, 2019-11, Vol.381 (21), p.2020-2031
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2019
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Patients with advanced non–small-cell lung cancer with a PD-L1 expression level of 1% or more of tumor cells were randomly assigned to receive nivolumab plus ipilimumab, nivolumab alone, or chemotherapy. Overall survival was significantly longer among the patients who received nivolumab plus ipilimumab than among those who received chemotherapy.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1910231Titel-ID: cdi_hal_primary_oai_HAL_hal_02528435v1
- Format
- –
- Schlagworte
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological, Antineoplastic Agents, Immunological - administration & dosage, Antineoplastic Agents, Immunological - adverse effects, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Apoptosis, B7-H1 Antigen, B7-H1 Antigen - metabolism, Biomarkers, Cancer therapies, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung - drug therapy, Carcinoma, Non-Small-Cell Lung - metabolism, Carcinoma, Non-Small-Cell Lung - mortality, Cellular Biology, Chemotherapy, Clinical medicine, Drug dosages, Female, Humans, Immunotherapy, Ipilimumab, Ipilimumab - administration & dosage, Ipilimumab - adverse effects, Life Sciences, Lung cancer, Lung Neoplasms, Lung Neoplasms - drug therapy, Lung Neoplasms - metabolism, Lung Neoplasms - mortality, Male, Middle Aged, Monoclonal antibodies, Mutation, Nivolumab, Nivolumab - administration & dosage, Nivolumab - adverse effects, Non-small cell lung carcinoma, Oncology, PD-L1 protein, Small cell lung carcinoma, Survival Analysis, Targeted cancer therapy, Tumors